| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 76996 |
Azidoethyl-SS-ethylazide CAS:352305-38-5 |
96 |
zyl |
2024-12-19 |
| 76997 |
CAS: 870487-09-5， Boc-Val-Cit-PAB |
92 |
WYQ |
2024-12-19 |
| 76998 |
cas:2101206-67-9，Ald-Ph-amido-PEG1-C2-Pfp ester， ADC试剂 |
81 |
kx |
2024-12-19 |
| 76999 |
Ald-Ph-amido-PEG11-NH-Boc CAS:1245813-70-0 |
126 |
zyl |
2024-12-19 |
| 77000 |
HSA-2-iminothiolane-DOTA HSA-2-亚氨基硫醇-DOTA |
105 |
h |
2024-12-19 |
| 77001 |
cas:1222787-24-7，2,5-Dioxopyrrolidin-1-yl 4-((2-((2-(2-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,9-tetrahydro-1H-purin-8-yl)phenoxy)acetamido)ethyl)amino)ethyl)disulfanyl)-4-oxobutanoate |
215 |
kx |
2024-12-19 |
| 77002 |
Tr-PEG5-OH CAS:141282-24-8物理化学性质 |
107 |
zyl |
2024-12-19 |
| 77003 |
CAS: 870487-08-4，Boc-Val-Cit，(S)-2-((S)-2-((叔丁氧基羰基)氨基)-3-甲基丁酰胺基)-5-脲基戊酸 |
105 |
WYQ |
2024-12-19 |
| 77004 |
DOTA-8-Aoc-BBN[7-14]NH |
122 |
h |
2024-12-19 |
| 77005 |
Fmoc-PEG3-Val-Cit，N-Fluorenylmethoxycarbonyl-triethylene glycol-Val-Cit |
101 |
WYQ |
2024-12-19 |
| 77006 |
CAS: 2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP |
86 |
WYQ |
2024-12-19 |
| 77007 |
CAS: 2055024-64-9，Azido-PEG4-Val-Cit-PAB-OH |
105 |
WYQ |
2024-12-19 |
| 77008 |
CAS: 870487-09-5，Boc-Val-Cit-PAB |
98 |
WYQ |
2024-12-19 |
| 77009 |
CAS:784105-33-5 Amino-PEG3-C2-acid的介绍 |
81 |
zyl |
2024-12-19 |
| 77010 |
CAS 863971-53-3：Fmoc-Val-Cit-PAB-PNP |
96 |
WYQ |
2024-12-19 |
| 77011 |
Ald-Ph-amido-PEG11-C2-NH2 CAS:1337889-01-6 |
81 |
zyl |
2024-12-19 |
| 77012 |
cas:2003260-13-5 ， MA-PEG4-Ala-Ala-PAB-PNP，ADC定制 |
85 |
wyh |
2024-12-19 |
| 77013 |
DOTA-NCS-6-Ahx-Phe 19-ST[1-19] DOTA偶联ST肽类似物 |
112 |
h |
2024-12-19 |
| 77014 |
1,4,7,10-四氮杂-n-(1-羧基-3-(4-硝基苯基)丙基)-n,N , N ‴-tris(acetic酸)环十二烷(PA-DOTA) |
81 |
h |
2024-12-19 |
| 77015 |
CAS 159858-22-7：Fmoc-Val-Cit-PAB-OH |
84 |
WYQ |
2024-12-19 |
| 77016 |
cas:5117-19-1，Octanethyl glycol ，八乙二醇的主要特点 |
124 |
zyl |
2024-12-19 |
| 77017 |
CAS 159857-79-1：Val-Cit-PAB-OH，缬氨酸（Val）、琥珀酰亚胺（Cit）和对氨基苯甲酸（PAB）的衍生物 |
122 |
WYQ |
2024-12-19 |
| 77018 |
SPDP-Val-Cit-PAB-OH，ADC定制 |
79 |
wyh |
2024-12-19 |
| 77019 |
DOTA-LVT 螯合剂DOTA偶联Lys8-血管收缩素 |
137 |
h |
2024-12-19 |
| 77020 |
cas:2054345-67-2，azido-tris(ethylenoxy)-L-alanine TFA Salt化学性质 |
98 |
zyl |
2024-12-19 |
| 77021 |
cas:68617-64-1，SPDP acid，3-(2-吡啶二硫代)丙酸的合成方法 |
128 |
zyl |
2024-12-19 |
| 77022 |
1,4,7,10-四(羧甲基)-1,4,7,10-四氮杂环十二烷单酰胺偶联葡萄糖 |
107 |
h |
2024-12-19 |
| 77023 |
PEG-P(Asp-Gd-DOTA)Gd‐DOTA偶联聚乙二醇改性聚天冬氨酸 |
105 |
h |
2024-12-19 |
| 77024 |
cas:70539-42-3，EGS Crosslinker，乙二醇-双(琥珀酸N-羟基琥珀酰亚胺酯)的结构式 |
191 |
zyl |
2024-12-19 |
| 77025 |
CXCR4导向的五肽[(68)Ga]喷替沙福(环(-D-Tyr-N-Me-D-Orn(AMB-DOTA)-L-Arg-L-2-Nal-Gly-)) |
148 |
h |
2024-12-19 |
| 77026 |
α-hexadecyl-DOTA α-十六烷基-DOTA |
97 |
h |
2024-12-19 |
| 77027 |
Methyltetrazine-SS-NHS 甲基四唑-双硫键-活性酯的合成方法 |
90 |
zyl |
2024-12-19 |
| 77028 |
DOTA-AgRP-6E |
134 |
h |
2024-12-19 |
| 77029 |
DOTA-morab-003 DOTA偶联单克隆抗体MORAb-003 |
90 |
h |
2024-12-19 |
| 77030 |
DOTA-Bz-folate DOTA-Bz-叶酸 |
106 |
h |
2024-12-19 |
| 77031 |
cas:55750-53-3，6-Maleimidocaproic acid，6-马来酰亚氨基己酸 |
130 |
zyl |
2024-12-19 |
| 77032 |
cas: Fmoc-PEG3-Val-Cit，ADC定制 |
108 |
wyh |
2024-12-19 |
| 77033 |
钆(III)DOTA-DSPE脂质体 |
102 |
h |
2024-12-19 |
| 77034 |
CAS: 870487-08-4，Boc-Val-Cit，叔丁氧羰基-缬氨酰-L-瓜氨酸 |
83 |
WYQ |
2024-12-19 |
| 77035 |
DOTA-Phe-D-Trp-Lys-Thr-OMe DOTA偶联生长抑素四肽类似物 |
120 |
h |
2024-12-19 |
| 77036 |
CAS: 35665-38-4，Fmoc-Gly-Gly-OH，Fmoc-甘氨酰-甘氨酸 |
121 |
WYQ |
2024-12-19 |
| 77037 |
cas:117235-10-6，3-Mercaptopropanyl-N-hydroxysuccinimide ester的结构式 |
122 |
zyl |
2024-12-19 |
| 77038 |
DOTA-PEG(4)-BBN(7-14)-AuNP DOTA-神经介素n功能化NHS活化的PEG-金纳米颗粒 |
86 |
h |
2024-12-19 |
| 77039 |
cas:2226472-28-0，DBCO-PEG4-Val-Cit-PAB-PNP，ADC定制 |
74 |
wyh |
2024-12-19 |
| 77040 |
CAS: 863971-53-3，Fmoc-Val-Cit-PAB-PNP |
96 |
WYQ |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询